PDF(Sci-hub)
Abstract：
UNASSIGNED: Recurrence of anti-glomerular basement membrane (anti-GBM) glomerulonephritis in the kidney graft is a rare event, described in limited reports. The aim of this study was to evaluate, in a large cohort of patients with long follow-up, the risk of recurrence of anti-GBM disease, the risk factors associated with clinical recurrence, and the long-term patient and graft survival.
UNASSIGNED: This was a multicenter retrospective study. Inclusion criteria were patients with anti-GBM glomerulonephritis who underwent transplantation of a kidney between 1977 and 2015. Exclusion criteria were systemic vasculitis, lupus erythematosus, and cryoglobulinemia. Recurrence was defined as reappearance of clinical signs of glomerulonephritis along with histological signs of proliferative glomerulonephritis and linear IgG staining on kidney biopsy, with or without anti-GBM antibodies.
UNASSIGNED: A total of 53 patients were included. Recurrence of anti-GBM glomerulonephritis in a first kidney transplant occurred in only 1 patient 5 years after transplantation (a prevalence rate of 1.9%) in the context of cessation of immunosuppressive drugs, and resulted in graft loss due to recurrence. Linear IgG staining on kidney biopsy in the absence of histological signs of proliferative glomerulonephritis was observed in 4 patients, in the context of cellular rejection. Patient survival was 100%, 94%, and 89% at 5, 10, and 15 years, respectively. Death-censored first-graft survival rates were 88%, 83%, and 79% at 5, 10, and 15 years, respectively.
UNASSIGNED: The recurrence rate of anti-GBM glomerulonephritis after transplantation is very low but is associated with graft loss. The long-term patient and graft survival rates are excellent.
UNASSIGNED: This was a multicenter retrospective study. Inclusion criteria were patients with anti-GBM glomerulonephritis who underwent transplantation of a kidney between 1977 and 2015. Exclusion criteria were systemic vasculitis, lupus erythematosus, and cryoglobulinemia. Recurrence was defined as reappearance of clinical signs of glomerulonephritis along with histological signs of proliferative glomerulonephritis and linear IgG staining on kidney biopsy, with or without anti-GBM antibodies.
UNASSIGNED: A total of 53 patients were included. Recurrence of anti-GBM glomerulonephritis in a first kidney transplant occurred in only 1 patient 5 years after transplantation (a prevalence rate of 1.9%) in the context of cessation of immunosuppressive drugs, and resulted in graft loss due to recurrence. Linear IgG staining on kidney biopsy in the absence of histological signs of proliferative glomerulonephritis was observed in 4 patients, in the context of cellular rejection. Patient survival was 100%, 94%, and 89% at 5, 10, and 15 years, respectively. Death-censored first-graft survival rates were 88%, 83%, and 79% at 5, 10, and 15 years, respectively.
UNASSIGNED: The recurrence rate of anti-GBM glomerulonephritis after transplantation is very low but is associated with graft loss. The long-term patient and graft survival rates are excellent.
摘要：
■肾移植中抗肾小球基底膜（抗GBM）肾小球肾炎的复发是罕见的事件，在有限的报告中描述。这项研究的目的是评估，在大量长期随访的患者中，抗GBM疾病复发的风险，与临床复发相关的危险因素，以及患者和移植物的长期存活。
■这是一项多中心回顾性研究。纳入标准是在1977年至2015年之间接受肾脏移植的抗GBM肾小球肾炎患者。排除标准为系统性血管炎,红斑狼疮,和冷球蛋白血症.复发定义为肾小球肾炎的临床体征以及增殖性肾小球肾炎的组织学体征和肾活检的线性IgG染色的再现。有或没有抗GBM抗体。
■共纳入53例患者。在停止免疫抑制药物的情况下，首次肾移植中抗GBM肾小球肾炎的复发仅发生在移植后5年的1例患者中（患病率为1.9％），并因复发而导致移植物丢失。在4例患者中，在没有增生性肾小球肾炎的组织学征象的情况下，在肾活检上观察到线性IgG染色。在细胞排斥的背景下。患者生存率为100%,94%,89%在5年、10年和15年，分别。死亡审查的首次移植存活率为88%，83%,在5年、10年和15年时为79%，分别。
■移植后抗GBM肾小球肾炎的复发率非常低，但与移植物丢失有关。患者和移植物的长期存活率是极好的。
■这是一项多中心回顾性研究。纳入标准是在1977年至2015年之间接受肾脏移植的抗GBM肾小球肾炎患者。排除标准为系统性血管炎,红斑狼疮,和冷球蛋白血症.复发定义为肾小球肾炎的临床体征以及增殖性肾小球肾炎的组织学体征和肾活检的线性IgG染色的再现。有或没有抗GBM抗体。
■共纳入53例患者。在停止免疫抑制药物的情况下，首次肾移植中抗GBM肾小球肾炎的复发仅发生在移植后5年的1例患者中（患病率为1.9％），并因复发而导致移植物丢失。在4例患者中，在没有增生性肾小球肾炎的组织学征象的情况下，在肾活检上观察到线性IgG染色。在细胞排斥的背景下。患者生存率为100%,94%,89%在5年、10年和15年，分别。死亡审查的首次移植存活率为88%，83%,在5年、10年和15年时为79%，分别。
■移植后抗GBM肾小球肾炎的复发率非常低，但与移植物丢失有关。患者和移植物的长期存活率是极好的。
